Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
GlobalRPh RX List - NESINA
Product / population
Alogliptin - NESINA tablets; selected source sections, not a full prescribing monograph.
Renal method
Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
NESINA: single-agent renal dosing is not combination eligibility
Alogliptin renal doses and HD timing do not determine eligibility for an alogliptin/metformin fixed combination. Peritoneal dialysis remains unstudied.
What to reconcile: Check every component and the dialysis modality before applying the single-agent schedule.
GlobalRPh-hosted RX List · Alogliptin - NESINA tablets; selected source sections, not a full prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Assess renal function before treatment and periodically. At CrCl >=60 mL/min, no adjustment is needed. At CrCl >=30 to <60, use 12.5 mg once daily. At CrCl >=15 to <30 or ESRD (<15 or hemodialysis), use 6.25 mg once daily. Dosing need not be timed to hemodialysis. Peritoneal dialysis has not been studied. This single-agent guidance is not the renal eligibility rule for an alogliptin/metformin fixed combination.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.